{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:41:40Z","timestamp":1772430100577,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41440-018-0014-8","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T06:33:29Z","timestamp":1518676409000},"page":"230-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pleiotropic effects of calcium channel blockers"],"prefix":"10.1038","volume":"41","author":[{"given":"Shigeru","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,15]]},"reference":[{"key":"14_CR1","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/01.hjh.0000249684.76296.4f","volume":"24","author":"T Inoue","year":"2006","unstructured":"Inoue T, Node K. Vascular failure\u2014a new clinical entity for vascular disease. J Hypertens. 2006;24:2121\u201330.","journal-title":"J Hypertens"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10557-007-6038-y","volume":"21","author":"T Inoue","year":"2007","unstructured":"Inoue T, Node K. Statin therapy for vascular failure. Cardiovasc Drug Ther. 2007;21:281\u201395.","journal-title":"Cardiovasc Drug Ther"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/157016111794519336","volume":"9","author":"I Taguchi","year":"2011","unstructured":"Taguchi I, Inoue T, Kikuchi M, Toyoda S, Arikawa T, Abe S, Node K. Pleiotropic effects of angiotensin receptor blockers on dyslipidemia. Curr Vasc Pharmacol. 2011;9:129\u201335.","journal-title":"Curr Vasc Pharmacol"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/hr.2016.183","volume":"40","author":"D Sueta","year":"2017","unstructured":"Sueta D, Tabata N, Hokimoto S. Clinical roles of calcium channel blockers in ischemic heart diseases. Hypertens Res. 2017;40:423\u20138.","journal-title":"Hypertens Res"},{"key":"14_CR5","first-page":"141","volume":"29","author":"S Yamagishi","year":"2003","unstructured":"Yamagishi S, Inagaki Y, Abe R, Kikuchi S, Sasaki N, Takeuchi M. Nifedipine inhibits apototic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha. Drug Exp Clin Res. 2003;29:141\u20135.","journal-title":"Drug Exp Clin Res"},{"key":"14_CR6","first-page":"147","volume":"29","author":"S Yamagishi","year":"2003","unstructured":"Yamagishi S, Inagaki Y, Kikuchi S. Nifedipine inhibit tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drug Exp Clin Res. 2003;29:147\u201352.","journal-title":"Drug Exp Clin Res"},{"key":"14_CR7","first-page":"163","volume":"30","author":"S Yamagishi","year":"2004","unstructured":"Yamagishi S, Takeuchi M. Nifedipine inhibit tumor necrosis factor-alpha-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule (VCAM)-1 expression. Drug Exp Clin Res. 2004;30:163\u20138.","journal-title":"Drug Exp Clin Res"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/00005344-200405000-00016","volume":"43","author":"S Yamagishi","year":"2004","unstructured":"Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol. 2004;43:724\u201330.","journal-title":"J Cardiovasc Pharmacol"},{"key":"14_CR9","first-page":"215","volume":"31","author":"T Matsui","year":"2005","unstructured":"Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res. 2005;31:215\u20139.","journal-title":"Drugs Exp Clin Res"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.atherosclerosis.2007.03.036","volume":"196","author":"K Nakano","year":"2008","unstructured":"Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis. 2008;196:172\u20139.","journal-title":"Atherosclerosis"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1097\/01.hjh.0000242414.96277.95","volume":"24","author":"K Nakano","year":"2006","unstructured":"Nakano K, Egashira K, Tada H, Kohjimoto Y, Hirouchi Y, Kitajima S, Endo Y, Li XH, Sunagawa K. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. J Hypertens. 2006;24:1881\u20139.","journal-title":"J Hypertens"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10641960903254414","volume":"32","author":"H Komoda","year":"2010","unstructured":"Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010;32:121\u20138.","journal-title":"Clin Exp Hypertens"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ajh.2007.13","volume":"21","author":"E Shima","year":"2008","unstructured":"Shima E, Katsube M, Kato T, Kitagawa M, Hato F, Hino M, Takahashi T, Fujita H, Kitagawa S. Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens. 2008;21:78\u201384.","journal-title":"Am J Hypertens"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ajh\/hpt202","volume":"27","author":"RP Mason","year":"2014","unstructured":"Mason RP, Jacob RF, Corbalan JJ, Kaliszan R, Malinski T. Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Am J Hypertens. 2014;27:482\u20138.","journal-title":"Am J Hypertens"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1016\/j.ijcard.2013.04.041","volume":"168","author":"X Liu","year":"2013","unstructured":"Liu X, Zhang GX, Zhang XY, Xia WH, Yang Z, Su C, Qiu YX, Xu SY, Zhan H, Tao J. Lacidipine improves endothelial repair capacity of endothelial progenitor cells from patients with essential hypertension. Int J Cardiol. 2013;168:3317\u201326.","journal-title":"Int J Cardiol"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217\u201325.","journal-title":"JAMA"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1253\/circj.CJ-09-0743","volume":"74","author":"N Kubota","year":"2010","unstructured":"Kubota N, Miyauchi K, Kasai T, Iesaki T, Kajimoto K, Sumiyoshi K, Dohi T, Daida H. Synergistic effects of calcium-channel and angiotensin-receptor blockers on endothelial function and inflammatory responses in a porcine drug-eluting stent mode. Circ J. 2010;74:1704\u201310.","journal-title":"Circ J"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/hr.2014.136","volume":"38","author":"K Nagasawa","year":"2015","unstructured":"Nagasawa K, Takahashi K, Matsuura N, Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T, Nagata K. Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertens Res. 2015;38:39\u201347.","journal-title":"Hypertens Res"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1254\/jphs.13178FP","volume":"124","author":"T Okamura","year":"2014","unstructured":"Okamura T, Tawa M, Geddawy A, Shimosato T, Iwasaki H, Shintaku H, Yoshida Y, Masada M, Shinozaki K, Imamura T. Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. J Pharmacol Sci. 2014;124:76\u201385.","journal-title":"J Pharmacol Sci"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0014-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:18:36Z","timestamp":1684617516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-018-0014-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1038\/s41440-018-0014-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,15]]},"assertion":[{"value":"5 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TI has received honorariums from Mochida, Bayer, and Boehringer Ingelheim. KN has received honorariums from Boehringer Ingelheim, Daiichi Sankyo, Astellas, MSD, Takeda, Mitsubishi Tanabe and Sanofi, and research grants from Sanwa Kagaku Kenkyusho, Astellas, Takeda, Boehringer Ingelheim, Teijin, and Mitsubishi Tanabe. The remaining authors declare that the have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}